Millendo Therapeutics was a clinical-stage biopharmaceutical company focused on developing treatments for endocrine diseases and orphan indications. The company specialized in creating therapies for rare endocrine disorders, with a particular focus on conditions affecting hormone regulation and metabolic processes.
Founded to address unmet medical needs in endocrinology, Millendo developed a pipeline of drug candidates targeting various hormonal and metabolic disorders. The company went public and raised capital to advance its clinical programs, but faced challenges in drug development. In 2021, Millendo ceased operations and underwent liquidation after its clinical programs did not meet advancement criteria, representing the high-risk nature of biotech drug development in specialized therapeutic areas.
Millendo Therapeutics has received investment from 1 venture capital firm.
Clinical-stage biopharmaceutical company developing treatments for rare endocrine diseases and hormonal disorders, ceased operations in 2021.
Millendo Therapeutics has received investment from GreatPoint Ventures. These venture capital firms and investors provide both capital and strategic support.
Millendo Therapeutics operates in the Biotech sector. Clinical-stage biopharmaceutical company developing treatments for rare endocrine diseases and hormonal disorders, ceased operations in 2021.
